This agreement expands Meditrina’s clinical stage product portfolio which currently includes Femathina (MPI- 674), an aromatase inhibitor (AI) that Meditrina is repurposing for the treatment of several serious women’s health conditions, including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).
John Patterson, executive director, R&D, AstraZeneca, said: “Anastrozole in combination with an estrogen and progestin in the area of women’s gynecologic indications represents a valid medical approach and sits well with Meditrina’s strategic focus and expertise.”